



Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction

Ryan Wereski, MD;* Dorien M. Kimenai, PhD;* Caelan Taggart¹, MD; Dimitrios Doudesis¹, MSc; Kuan Ken Lee, MD; Matthew T.H. Lowry, MD; Anda Bularga, MD; David J. Lowe¹, MD; Takeshi Fujisawa, PhD; Fred S. Apple, PhD; Paul O. Collinson, MD, PhD; Atul Anand, MD, PhD; Andrew R. Chapman, MD, PhD; Nicholas L. Mills¹, MD, PhD

BACKGROUND: Although the 99th percentile is the recommended diagnostic threshold for myocardial infarction, some guidelines also advocate the use of higher troponin thresholds to rule in myocardial infarction at presentation. It is unclear whether the magnitude or change in troponin concentration can differentiate causes of myocardial injury and infarction in practice.

METHODS: In a secondary analysis of a multicenter randomized controlled trial, we identified 46092 consecutive patients presenting with suspected acute coronary syndrome without ST-segment-elevation myocardial infarction. High-sensitivity cardiac troponin I concentrations at presentation and on serial testing were compared between patients with myocardial injury and infarction. The positive predictive value and specificity were determined at the sex-specific 99th percentile upper reference limit and rule-in thresholds of 64 ng/L and 5-fold of the upper reference limit for a diagnosis of type 1 myocardial infarction.

RESULTS: Troponin was above the 99th percentile in 8188 patients (18%). The diagnosis was type 1 or type 2 myocardial infarction in 50% and 14% and acute or chronic myocardial injury in 20% and 16%, respectively. Troponin concentrations were similar at presentation in type 1 (median [25th–75th percentile] 91 [30–493] ng/L) and type 2 (50 [22–147] ng/L) myocardial infarction and in acute (50 [26–134] ng/L) and chronic (51 [31–130] ng/L) myocardial injury. The 99th percentile and rule-in thresholds of 64 ng/L and 5-fold upper reference limit gave a positive predictive value of 57% (95% CI, 56%–58%), 59% (58%–61%), and 62% (60%–64%) and a specificity of 96% (96%–96%), 96% (96%–96%), and 98% (97%–98%), respectively. The absolute, relative, and rate of change in troponin concentration were highest in patients with type 1 myocardial infarction ($P<0.001$ for all). Discrimination improved when troponin concentration and change in troponin were combined compared with troponin concentration at presentation alone (area under the curve, 0.661 [0.642–0.680] versus 0.613 [0.594–0.633]).

CONCLUSIONS: Although we observed important differences in the kinetics, cardiac troponin concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from other causes of myocardial injury or infarction in practice and should not guide management decisions in isolation.

REGISTRATION: URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT01852123.

Key Words: kinetics ■ myocardial infarction ■ predictive value of tests ■ troponin

Correspondence to: Nicholas L. Mills, MD, PhD, BHF/University Centre for Cardiovascular Science, Royal Infirmary of Edinburgh, University of Edinburgh, Edinburgh EH16 4SA, UK. Email nick.mills@ed.ac.uk

This manuscript was sent to Prof. Allan Jaffe, Guest Editor, for review by expert referees, editorial decision, and final disposition.

*Drs Wereski and Kimenai contributed equally.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/circulationaha.121.054302>.

For Sources of Funding and Disclosures, see page 537.

© 2021 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Circulation is available at www.ahajournals.org/journal/circ

Clinical Perspective

What Is New?

- In 46 092 consecutive patients with suspected acute coronary syndrome, we evaluated the performance of the 99th percentile rule-in threshold and thresholds of 64 ng/L and 5 times the upper reference limit for the diagnosis of type 1 myocardial infarction.
- Troponin concentrations at presentation have a low positive predictive value for type 1 myocardial infarction, and a threshold 50 times the upper reference limit is required to achieve a positive predictive value $\geq 70\%$.
- Change in troponin on serial testing only marginally improves positive predictive value for type 1 myocardial infarction over presenting troponin alone (area under curve, 0.661 [0.642–0.680] versus 0.613 [0.594–0.633]).

What Are the Clinical Implications?

- Troponin concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from other causes of myocardial injury or infarction and should not be used in isolation to guide management decisions in patients with suspected acute coronary syndrome.

Nonstandard Abbreviations and Acronyms

High-STEACS	High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome
PPV	positive predictive value
URL	upper reference limit

To promote the adoption of common standards, the Universal Definition of Myocardial Infarction recommends cardiac troponin testing and the 99th percentile upper reference limit (URL) as the diagnostic threshold for myocardial infarction.¹ In practice, there are many causes of troponin elevation, with about half of all increases attributable to conditions other than type 1 myocardial infarction.^{2–9} Nonetheless, the early differentiation between types of myocardial infarction and acute or chronic nonischemic myocardial injury is important because the immediate management of these conditions differs.^{1,10,11} Prompt treatment with antiplatelet agents, anticoagulation, and coronary revascularization is recommended in type 1 myocardial infarction, whereas these may not be indicated in type 2 myocardial infarction or myocardial injury and may be contraindicated.^{8,12}

Alternative thresholds above the 99th percentile have been proposed to improve the positive predictive value

(PPV) and specificity of troponin for type 1 myocardial infarction.^{11,13–16} The European Society of Cardiology guidelines propose the use of rule-in thresholds above the 99th percentile to guide admission to cardiology and coronary angiography.¹¹ These rule-in thresholds and those 5 times the URL are purported to give a PPV of at least 70% and 90%, respectively.¹¹ They were derived in selected patients with chest pain, but, in practice, troponin testing is applied more widely to evaluate patients with suspected acute coronary syndrome presenting with a broader range of symptoms.^{3,17} Guidelines also recommend serial testing with a rise or fall in cardiac troponin needed to confirm the diagnosis of myocardial infarction.^{1,10,11,18} However, patients with type 2 myocardial infarction and acute nonischemic myocardial injury also have dynamic changes in troponin concentration on serial testing.^{19–21} It is unclear whether rule-in thresholds or troponin kinetics can reliably differentiate between types of myocardial infarction or between myocardial injury and infarction in clinical practice.²²

We aimed to evaluate the performance of recommended cardiac troponin thresholds to rule in the diagnosis of type 1 myocardial infarction at presentation. We also aimed to determine whether the kinetics of cardiac troponin differs sufficiently to discriminate between myocardial injury and infarction.²³

METHODS

Transparency and Openness Promotion

The High-STEACS trial (High-Sensitivity Troponin in the Evaluation of Patients With Suspected Acute Coronary Syndrome) makes use of multiple routine electronic health care data sources that are linked, deidentified, and held in a national safe haven that is accessible by approved individuals who have undertaken the necessary governance training. Summary data and the analysis code can be made available on request from the corresponding author.

Study Population and Trial Design

High-STEACS is a stepped-wedge cluster randomized controlled trial that evaluated the implementation of a high-sensitivity cardiac troponin I assay in consecutive patients with suspected acute coronary syndrome across 10 secondary and tertiary care hospitals in Scotland. A detailed description of this trial has been reported elsewhere,² but in summary, all patients attending the emergency department were screened for suspected acute coronary syndrome by the attending clinician at the time cardiac troponin was requested with the use of an electronic form integrated into the clinical care pathway. Patients were eligible for inclusion if they presented with suspected acute coronary syndrome and had paired cardiac troponin measurements from the standard care and trial assay. Patients were excluded if they had been admitted previously during the trial period or were not residents of Scotland. In this analysis, we excluded patients with ST-segment-elevation myocardial infarction,²⁴ those for whom troponin concentration

at presentation was missing, or patients for whom the adjudicators were unable to arrive at a consensus for the final diagnosis.

Measurement of Cardiac Troponin

Cardiac troponin testing was performed at presentation to hospital and was repeated 6 or 12 hours after the onset of symptoms at the discretion of the attending physician in accordance with national guidelines.^{25,26} All patients had troponin measured with a high-sensitivity cardiac troponin I assay (ARCHITECT_{STAT} high-sensitive troponin I assay; Abbott Laboratories, Abbott Park, IL). This assay has an interassay coefficient of variation of <10% at 4.7 ng/L and a limit of detection of 1.2 and 1.9 ng/L. For consistency with prior studies, we defined the limit of detection as any concentration <2 ng/L, and for the purpose of this analysis, we assigned concentrations below the limit of detection a value of 1.0 ng/L.^{27,28} The assay has a 99th percentile URL of 26 ng/L, with sex-specific thresholds of 34 and 16 ng/L in men and women, respectively.^{29,30}

Diagnostic Adjudication

All patients with any high-sensitivity cardiac troponin I concentration above the sex-specific 99th percentile were adjudicated and classified according to the Fourth Universal Definition of Myocardial Infarction.¹ Two physicians independently reviewed all clinical information, with discordant diagnoses resolved by a third physician. Type 1 myocardial infarction was defined as myocardial necrosis (any high-sensitivity cardiac troponin I concentration above the sex-specific 99th percentile with a rise or fall in troponin when serial testing was performed) in the context of a presentation with suspected acute coronary syndrome and symptoms or signs of myocardial ischemia on the ECG. Patients with myocardial necrosis, symptoms or signs of myocardial ischemia, and evidence of myocardial oxygen supply-demand imbalance secondary to an alternative condition without evidence of acute atherothrombosis were classified as having type 2 myocardial infarction.²¹ Patients with elevated troponin concentrations without symptoms or signs of myocardial ischemia were classified as having nonischemic myocardial injury. All nonischemic myocardial injury was classified as acute unless troponin concentrations changed $\leq 20\%$ on serial testing in accordance with the universal definition or if the adjudicated diagnosis was chronic heart failure or chronic renal failure, for which the classification was chronic myocardial injury. A detailed summary of the adjudication procedures is provided in the [Data Supplement](#).

Ethics Approval

The study was approved by the Scotland A Research Ethics Committee, by the Public Benefit and Privacy Panel for Health and Social Care, and by each National Health Service Health Board. Individual patient consent was not required, and data from consecutive patients were collected prospectively from the electronic record, deidentified, and linked within secure National Health Service Safe Havens.

Patient and Public Involvement

Patients and lay representatives were members of the steering committee for the trial and all related studies and were involved in the design, conduct, and approval of the High-STEACS trial.

Statistical Analysis

Baseline characteristics were summarized for the study population and in groups according to the diagnostic classification: type 1 myocardial infarction, type 2 myocardial infarction, acute myocardial injury, chronic myocardial injury, and no myocardial injury. Group-wise comparisons were performed with χ^2 , Kruskal-Wallis, or 1-way ANOVA tests as appropriate. We constructed confusion matrices and calculated the PPV and specificity for type 1 myocardial infarction of a high-sensitivity cardiac troponin I concentration at presentation above the uniform 99th percentile (26 ng/L), sex-specific 99th percentile (16 ng/L in women, 34 ng/L in men), guideline-recommended rule-in threshold of 64 ng/L, and 3-fold and 5-fold URL thresholds (78 and 130 ng/L, respectively). From prior literature, we also determined the cardiac troponin concentration at presentation that met a prespecified PPV of 75%.³¹ We calculated the 95% CI using a bayesian approach by sampling from a binomial likelihood with noninformative Jeffreys prior (both β -distribution shape parameters equal to 0.5). In a sensitivity analysis, we evaluated the PPV and specificity in patients for whom the primary presenting symptom recorded by the attending clinician was chest pain.

In patients with serial sampling within 12 hours of presentation, we used linear mixed-effects modeling with random slopes and intercepts to evaluate the relationship among symptom onset, troponin, and change in troponin concentration. Nonlinear associations were evaluated by adding a second-order polynomial term for time to the model. We have compared the models with and without a quadratic term for time, and the final model was chosen according to the lowest Akaike information criteria. To illustrate the kinetics of cardiac troponin across the groups, we developed additional models for each diagnostic classification. In each of these models, we included type 2 myocardial infarction or acute or chronic myocardial injury as a fixed effect, with type 1 myocardial infarction as the reference group. To evaluate whether relative or absolute change in troponin on serial testing improves discrimination for type 1 myocardial infarction over troponin concentration at presentation alone, we used logistic regression and compared the area under the receiver-operating characteristic curve. We evaluated models that incorporated relative and absolute changes as continuous measures and absolute and relative delta values of 15 ng/L and 20% as recommended in international guidelines.^{10,11} All analyses were performed in R (version 3.5.1).

RESULTS

The analysis population comprised 46 092 of the 48 242 patients enrolled in the trial after exclusion of those with ST-segment-elevation myocardial infarction ($n=925$), those for whom the diagnosis could not be adjudicated ($n=1241$), and those with missing troponin concentrations at presentation ($n=24$; [Figure 1 in the Data Supplement](#)).

Cardiac troponin concentrations were above the sex-specific 99th percentile URL in 8188 (18%) patients. The adjudicated diagnosis was type 1 myocardial infarction in 50% ($n=4064$), type 2 myocardial infarction in 14% ($n=1116$), acute myocardial injury in 20% ($n=1676$), and

chronic myocardial injury in 16% (n=1287) of patients (Table 1). Patients with type 1 myocardial infarction were younger and more likely to be men than those with type 2 myocardial infarction or acute and chronic myocardial injury. Chest pain was the primary presenting symptom in 90% of patients with type 1 myocardial infarction (3315 of 3692) and 73% of those with type 2 myocardial infarction (744 of 1026) but was less common

in patients with acute (38%, 569 of 1495) or chronic (49%, 559 of 1131) myocardial injury.

Troponin Concentrations at Presentation in Myocardial Injury and Infarction

At presentation, troponin concentrations were similar in type 1 (median [25th–75th percentile] 91 [30–493]

Table 1. Baseline Characteristics of the Study Population Stratified by Adjudicated Diagnosis of Myocardial Injury or Infarction

Variable	All participants	Type 1 myocardial infarction	Type 2 myocardial infarction	Acute myocardial injury	Chronic myocardial injury	No myocardial injury
No. of participants	46 092	4 064	1 116	1 676	1 287	37 904
Age, y	61.0 (49.0–75.0)	69.0 (58.0–80.0)	77.0 (67.0–84.0)	78.0 (68.0–86.0)	78.0 (65.5–85.0)	58.0 (47.0–71.0)
Male, n (%)	24 433 (53.0)	2 371 (58.3)	500 (44.8)	664 (39.6)	536 (41.6)	20 341 (53.7)
Presenting symptoms, n (%)*						
Chest pain	33 319 (81.6)	3 315 (89.8)	744 (72.5)	569 (38.1)	559 (49.4)	28 091 (84.0)
Dyspnea	1 977 (4.8)	146 (4.0)	116 (11.3)	372 (24.9)	235 (20.8)	1 107 (3.3)
Other	2 003 (4.9)	151 (4.1)	61 (5.9)	217 (14.5)	116 (10.3)	1 458 (4.4)
Palpitation	1 213 (3.0)	15 (0.4)	67 (6.5)	97 (6.5)	42 (3.7)	991 (3.0)
Syncope	2 332 (5.7)	65 (1.8)	38 (3.7)	240 (16.1)	179 (15.8)	1 808 (5.4)
Medical history, n (%)						
Coronary artery disease	11 349 (24.6)	1 408 (34.6)	454 (40.7)	509 (30.4)	492 (38.2)	8 444 (22.3)
Myocardial infarction	4 003 (8.7)	619 (15.2)	163 (14.6)	161 (9.6)	205 (15.9)	2 832 (7.5)
Diabetes	3 274 (7.1)	708 (17.4)	147 (13.2)	208 (12.4)	164 (12.7)	2 039 (5.4)
Cerebrovascular disease	2 732 (5.9)	323 (8.0)	135 (12.1)	192 (11.5)	167 (13.0)	1 914 (5.1)
Hypercholesterolemia	18 412 (39.9)	2 105 (51.8)	631 (56.5)	852 (50.8)	686 (53.3)	14 092 (37.2)
Heart failure	3 908 (8.5)	682 (16.8)	291 (26.1)	410 (24.5)	363 (28.2)	2 155 (5.7)
Abnormal renal function	8 398 (18.7)	1 246 (31.2)	536 (49.0)	855 (52.6)	642 (51.6)	5 112 (13.9)
Previous revascularization, n (%)						
Percutaneous coronary intervention	3 543 (7.7)	446 (11.0)	97 (8.7)	94 (5.6)	128 (9.9)	2 743 (7.2)
Coronary artery bypass grafting	747 (1.6)	101 (2.5)	32 (2.9)	45 (2.7)	34 (2.6)	534 (1.4)
ECG, n (%)†						
Normal	2 522 (37.3)	1 519 (43.2)	201 (19.6)	400 (34.3)	363 (36.8)	...
Myocardial ischemia	1 740 (25.7)	1 152 (32.8)	379 (36.9)	112 (9.6)	75 (7.6)	...
ST-segment depression	1 185 (17.5)	752 (21.4)	278 (27.0)	87 (7.5)	56 (5.7)	...
ST-segment elevation	243 (3.6)	129 (3.7)	31 (3.0)	38 (3.3)	40 (4.1)	...
T-wave inversion	1 191 (17.6)	733 (20.8)	166 (16.1)	128 (11.0)	148 (15.0)	...
Observations, hematology, and clinical chemistry						
Systolic blood pressure, mmHg	139.4 (28.9)	143.3 (27.3)	132.4 (29.9)	135.7 (31.2)	137.4 (28.6)	137.5 (23.3)
Heart rate, bpm	85.9 (26.4)	78.3 (18.9)	104.8 (35.1)	94.2 (29.2)	84.6 (23.9)	77.2 (25.3)
Hemoglobin, g/L	137.2 (18.2)	135.5 (19.7)	127.8 (25.3)	129.7 (21.6)	128.5 (20.6)	138.2 (17.2)
Presentation troponin, ng/L	3.0 (1.2–10.6)	91.0 (30.2–492.5)	49.5 (22.0–147.2)	50.0 (25.5–134.2)	51.1 (30.5–130.3)	2.2 (1.0–5.1)
Peak troponin, ng/L	3.6 (1.4–12.4)	538.4 (85.0–3584.9)	123.8 (48.1–599.7)	74.0 (37.1–307.1)	55.2 (34.1–144.7)	2.6 (1.0–6.0)

Values are presented as mean±SD or median (25th–75th percentile) as appropriate. ... indicates not applicable.

*Presenting symptoms are reported for the 87% (40 844/46 092) of patients for whom primary symptom data were available.

†Electrocardiographic data reported for the 82% (6739 of 8188) patients with myocardial infarction or myocardial injury who had electrocardiographic data available.

ng/L) and type 2 (50 [22–147] ng/L) myocardial infarction and in acute (50 [26–134] ng/L) and chronic (51 [31–130] ng/L) myocardial injury (Figure 1 and Table 1). A troponin concentration above the uniform 99th percentile at presentation gave a PPV of 48% and specificity of 92% for type 1 myocardial infarction (Table 2). The sex-specific 99th percentile of 16 ng/L in women gave a PPV and specificity of 39% and 89%, whereas the sex-specific 99th percentile of 34 ng/L in men gave a PPV and specificity of 56% and 93%, respectively. The rule-in threshold of 64 ng/L and 5-fold URL threshold gave PPVs of 57% and 62%, respectively, with specificities of 96% and 97% (Figure 2). To achieve a PPV of 75%, a rule-in threshold of 1303 ng/L was required, whereas no threshold gave a PPV of $\geq 90\%$.

In a sensitivity analysis restricted to 82% (33 319 of 40 844) of patients in whom the primary presenting symptom was chest pain (Table 1 in the Data Supplement), the PPV and specificity for type 1 myocardial infarction at the rule-in threshold of 64 ng/L were 72% and 98%, respectively (Table 2). The 5-fold URL threshold gave a PPV of 75% and a specificity of 99%. A rule-in threshold of 119 ng/L gave a PPV of 75%, but no threshold achieved a PPV of 90% in this population (Figure 2).

Troponin Kinetics in Myocardial Injury and Infarction

Serial troponin testing within 12 hours of presentation was performed in 4187 patients (51%) with concentrations above the sex-specific 99th percentile. The time from symptom onset to initial troponin sampling was

similar in patients with type 1 and type 2 myocardial infarction and acute myocardial injury (240 [180–420] minutes) but was longer in patients with chronic myocardial injury (300 [180–780] minutes). The rate of change in troponin within 12 hours of presentation was highest in patients with type 1 myocardial infarction compared with those with type 2 myocardial infarction and acute or chronic myocardial injury ($P < 0.001$ for all; Figure 3). The absolute change in troponin concentration differed in patients with type 1 myocardial infarction (177 [21–1929] ng/L) compared with those with type 2 myocardial infarction (46 [10–365] ng/L), acute nonischemic myocardial injury (57 [17–384] ng/L), and chronic myocardial injury (6 [2–22] ng/L; $P < 0.001$ for all; Figure 4). The relative change in troponin concentration also differed between patients with type 1 myocardial infarction (231% [31%–1602%]) compared with those with type 2 myocardial infarction (105% [22%–656%]), acute nonischemic myocardial injury (129% [45%–534%]), and chronic myocardial injury (12% [5%–24%]; $P < 0.001$ for all).

Combining troponin concentration at presentation with an absolute change in troponin on serial testing of ≥ 15 ng/L or relative change of $\geq 20\%$ improved discrimination for type 1 myocardial infarction compared with troponin concentration at presentation alone (0.646 [0.627–0.666] and area under the receiver operating characteristic curve, 0.661 [0.642–0.680], respectively, versus 0.613 [0.594–0.633]; Figure 11 in the Data Supplement).

DISCUSSION

In consecutive patients with suspected acute coronary syndrome, we evaluated whether troponin concentrations at presentation or their kinetics differed sufficiently to discriminate between myocardial injury and infarction. We report a number of observations that are relevant to practice. First, troponin concentrations at presentation are similar in patients with myocardial injury and those with infarction regardless of the diagnostic classification. Second, the use of recommended rule-in thresholds above the 99th percentile provides only marginal improvements in the PPV and specificity for type 1 myocardial infarction. Troponin thresholds > 1000 ng/L would be required to achieve a PPV of $\geq 75\%$. Third, the magnitude and rate of change of troponin can help differentiate type 1 from type 2 myocardial infarction and acute or chronic myocardial injury. Although we observed important differences in troponin kinetics, the troponin concentration at presentation provides only limited discrimination between type 1 myocardial infarction and other causes of myocardial injury or infarction. Clinical context may be more helpful than any given rule-in threshold to guide the triage and initial management of patients with suspected acute coronary syndrome in practice.




Figure 1. High-sensitivity cardiac troponin I concentrations at presentation in patients with myocardial injury and infarction.

Kernel density plot of presentation troponin concentration stratified by the adjudicated diagnosis: type 1 myocardial infarction (MI; red), type 2 MI (yellow), acute myocardial injury (blue), and chronic myocardial injury (gray).

Table 2. Diagnostic Performance of Cardiac Troponin Concentration at Presentation in All Patients With Suspected Acute Coronary Syndrome and in Those With a Primary Symptom of Chest Pain

Threshold	True positives, n	False positives, n	True negatives, n	False negatives, n	PPV, % (95% CI)	NPV, % (95% CI)	Sensitivity, % (95% CI)	Specificity, % (95% CI)	
All suspected acute coronary syndrome (n=46 068)									
Uniform 99th percentile	26 ng/L	3191	3466	38 562	873	47.9 (46.7–49.1)	97.8 (97.6–97.9)	78.5 (77.2–79.8)	91.8 (91.5–92.0)
Sex-specific 99th percentile	34 ng/L (men)	1876	1500	20 569	492	55.6 (53.9–57.3)	97.7 (97.4–97.9)	79.2 (77.6–80.9)	93.2 (92.9–93.5)
	16 ng/L (women)	1463	2256	17 703	230	39.3 (37.8–40.9)	98.7 (98.5–98.9)	86.5 (84.87–88.0)	88.7 (88.3–89.1)
Rule-in*	64 ng/L	2308	1734	40 294	1756	57.1 (55.6–58.6)	95.8 (95.6–96.0)	56.8 (55.3–58.3)	95.9 (95.7–96.1)
3 times URL	78 ng/L	2161	1494	40 534	1903	59.1 (57.5–60.7)	95.5 (95.3–95.7)	53.2 (51.6–54.7)	96.4 (96.3–96.6)
5 times URL	130 ng/L	1760	1073	40 955	2304	62.1 (60.3–63.9)	94.7 (94.5–94.9)	43.3 (41.8–44.8)	97.5 (97.3–97.6)
Primary symptom of chest pain (n=33 308)									
Uniform 99th percentile	26 ng/L	2577	1562	28 442	738	62.3 (60.8–63.7)	97.5 (97.3–97.7)	77.7 (76.3–79.1)	94.8 (94.5–95.0)
Sex-specific 99th percentile	34 ng/L (men)	1531	698	15 323	416	68.7 (66.7–70.6)	97.4 (97.1–97.6)	78.6 (76.8–80.4)	95.7 (95.3–96.0)
	16 ng/L (women)	1172	993	12 990	195	54.1 (52.0–56.2)	98.5 (98.3–98.7)	85.7 (83.8–87.5)	92.9 (92.5–93.3)
Rule-in*	64 ng/L	1847	733	29 271	1468	71.6 (69.8–73.3)	95.2 (95.0–95.5)	55.7 (54.0–57.4)	97.6 (97.4–97.7)
3 times URL	78 ng/L	1727	632	29 372	1588	73.2 (71.4–75.0)	94.9 (94.6–95.1)	52.1 (50.4–53.8)	97.9 (97.7–98.1)
5 times URL	130 ng/L	1388	447	29 557	1927	75.6 (73.6–77.6)	93.9 (93.6–94.1)	41.9 (40.2–43.6)	98.5 (98.4–98.6)

NPV indicates negative predictive value; PPV, positive predictive value; and URL, upper reference limit.

*Rule-in threshold recommended in the European Society of Cardiology 0/1-hour and 0/2-hour early rule-out and rule-in algorithms.¹¹

In contrast with the previous generation of cardiac troponin assays, high-sensitivity assays are able to precisely measure troponin at very low concentrations. Accelerated diagnostic pathways that harness this enhanced precision to enable earlier decisions to rule out and rule in myocardial infarction are now used widely around the world and have been recommended by international guidelines.^{1,11,32,33} The diagnostic performance of these pathways has been validated in multiple observational studies,^{16,34–38} and the effectiveness and safety of ruling out myocardial infarction earlier have been demonstrated in randomized controlled trials.^{39,40} However, the only prior randomized trial to evaluate the effectiveness of applying the 99th percentile to rule in myocardial infarction did not demonstrate better outcomes.⁴¹

The major advantage of accelerated diagnostic pathways using high-sensitivity cardiac troponin testing is that they improve confidence to rule out myocardial infarction and to reduce the need for admission to hospital.^{24,39,40} However, the use of lower thresholds to diagnose myocardial infarction has identified more patients with elevated cardiac troponin concentrations attributable to other conditions.^{2,3,9} Therefore, thresholds above the 99th percentile have been proposed to improve the specificity and PPV and to accelerate the rule-in of myocardial infarction. Assay-specific rule-in thresholds are recommended by the European Society of Cardiology practice guidelines, which also advocate that patients with troponin concentrations above these thresholds

at presentation be triaged to a coronary care unit and undergo coronary angiography.¹¹ However, the performance of these rule-in thresholds has not been evaluated in clinical practice, where testing is often performed in a broader group of patients. Our findings are consistent with the concept that underpins these recommendations: the higher the troponin concentration at presentation, the higher the likelihood of type 1 myocardial infarction. However, the PPV of the rule-in threshold was 57%, considerably lower than the 77% and 70% reported in the derivation and validation of this rule-in threshold.⁴² Our observations are consistent with a recent study-level meta-analysis that reported that the PPV of the rule-in component of a multithreshold 0/1-hour pathway using a high-sensitivity cardiac troponin T assay was 51%.⁴³ However, this was not a patient-level analysis, and the performance of the rule-in threshold in isolation was not reported. When our patient population was restricted to the 33 308 patients presenting with a primary symptoms of chest pain to enable direct comparison with those studies in which the rule-in threshold was defined, we observed a substantial improvement in the PPV to 72%. Taken together, these observations highlight the importance of interpreting cardiac troponin in context and the merits of evaluating the performance of diagnostic tests in the population in which they are applied in practice.

In consecutive patients with suspected acute coronary syndrome, half of all patients with a concentration of troponin above the sex-specific 99th percentile had




Figure 2. Positive predictive value of high-sensitivity cardiac troponin I concentration at presentation for a diagnosis of type 1 myocardial infarction.

Positive predictive value and 95% CIs of high-sensitivity cardiac troponin I concentration at presentation for type 1 myocardial infarction in all patients with suspected acute coronary syndrome (blue) and in those with a primary symptom of chest pain (red). Dotted lines illustrate the positive predictive value of the uniform 99th percentile and 5-fold upper reference limit (URL).

a diagnosis of type 2 myocardial infarction or acute and chronic nonischemic myocardial injury. Our findings are consistent with those from the BACC study (Biomarkers in Acute Cardiac Care) in which just 29% of patients with an elevated cardiac troponin T concentration had a diagnosis of type 1 myocardial infarction.⁴⁴ Although we observed that troponin concentrations were higher in type 1 myocardial infarction, there was substantial overlap with type 2 myocardial infarction and myocardial injury, suggesting that troponin alone at any threshold cannot reliably discriminate between these conditions. Even at a threshold 5 times the URL, purported to have a PPV of >90%,¹¹ we observed that the PPV was just 62% for type 1 myocardial infarction. A threshold >50 times the URL would be required to achieve a PPV of 75% when applied to all patients with suspected acute coronary syndrome.

Although our observations highlight the limitations of using single troponin measurements to triage patients, confirmation of the diagnosis of myocardial infarction

requires serial testing and a rise or fall in cardiac troponin.¹ We observed differences in the rate of troponin release with a higher rate of change, as well as larger absolute and relative changes on serial sampling, in patients with type 1 myocardial infarction compared with those with type 2 myocardial infarction or acute and chronic myocardial injury. Despite these differences, the use of relative or absolute delta change criteria only marginally improved discrimination compared with the troponin concentration alone. This is perhaps not surprising given the observed changes in troponin concentration on serial testing in both type 2 myocardial infarction and acute myocardial injury. Although previous studies using a contemporary sensitive troponin assay in a small cohort of 66 and 188 patients with type 1 and type 2 myocardial infarction, respectively, suggested no improvement in discrimination when change in troponin at 3 or 6 hours was combined with the absolute concentration,⁴⁵ we observed a modest improvement. It would seem unlikely




Figure 3. Kinetics of high-sensitivity cardiac troponin I concentration from symptom onset in patients with myocardial injury and infarction.

Spaghetti plot illustrating high-sensitivity cardiac troponin I concentrations in relation to the time of symptom onset in individual patients stratified by the adjudicated diagnosis: type 1 myocardial infarction (red), type 2 myocardial infarction (yellow), acute myocardial injury (blue), and chronic myocardial injury (gray). Plot is restricted to those patients in whom any troponin concentration was above the sex-specific 99th percentile concentration during serial testing within 12 hours of presentation and for whom the time of symptom onset was known ($n=3845$). Linear mixed-effects modeling was done using random intercepts and random slopes, including quadratic terms for time, with cardiac troponin I as outcome. The output from a linear mixed-effects model incorporating time from symptom onset, troponin, and change in troponin concentration is overlaid for each condition. For each condition, the final model to estimate the trajectory of cardiac troponin I was chosen according to the Akaike information criteria.

that the shorter time intervals between serial testing would improve discrimination, but this should be evaluated in future studies.

In recent years, a number of approaches have been proposed that could enable clinicians to use cardiac troponin more flexibly.^{31,46,47} These approaches recognize the limitations of applying fixed thresholds to triage a heterogeneous population of patients and the challenge of performing serial testing at precise intervals in clinical

practice. The Troponin Only–Manchester Acute Coronary Syndrome rule uses logistic regression to provide individual patient risk estimates for non–ST-segment-elevation myocardial infarction by incorporating age, sex, clinical variables, and a measure of high-sensitivity cardiac troponin T at presentation. This rule performs well but does not discriminate type 1 myocardial infarction from other causes of troponin elevation or take into account serial testing.⁴⁷ In a collaborative analysis that




Figure 4. Absolute and relative changes in high-sensitivity cardiac troponin I concentration on serial testing in patients with myocardial injury and infarction.

Violin-density and box-and-whisker plots illustrating the absolute and relative change in high-sensitivity cardiac troponin I concentration on serial testing in patients stratified by the adjudicated diagnosis: type 1 myocardial infarction (red), type 2 myocardial infarction (yellow), acute myocardial injury (blue), and chronic myocardial injury (gray).

pooled data from multiple cohorts, the COMPASS-MI (Calculation of Myocardial Infarction Risk Probabilities to Manage Patients With Suspicion of Myocardial Infarction) investigators highlight that a more flexible approach is required and demonstrate proof of concept that the negative predictive value and PPV for type 1 myocardial infarction vary across a range of thresholds and delta change in troponin values.⁴⁶ Finally, the myocardial ischemic injury index uses a gradient-boosting machine learning algorithm to combine age, sex, and paired high-sensitivity cardiac troponin I values to compute a value (0–100) that reflects the likelihood of type 1 myocardial infarction for an individual patient.³¹ Serial testing can be performed at any time point, and the algorithm incorporates a measure of rate of change in troponin. Although each of these approaches shows considerable promise, it is unclear at present whether the use of these probabilistic scores in practice improves clinical decisions compared with existing guideline-recommended pathways using fixed thresholds.

We recognize some strengths and limitations of this study. First, we enrolled consecutive patients in whom the attending clinician suspected acute coronary syndrome by embedding our screening tool into the electronic health care system. This avoided selection bias and ensured that our study population was representative. Second, all diagnoses were adjudicated according to the Fourth Universal Definition of Myocardial Infarction, ensuring that our findings are relevant to contemporary practice. Although few patients had missing troponin values for the evaluation of rule-in thresholds (0.1%), serial testing was performed at the discretion of the attending clinician and was performed in only 53% of patients

with myocardial injury or infarction. It is likely that those patients undergoing serial testing differed from those who had a single test performed; however, our comparison between patients with type 1 and type 2 myocardial infarction and those with myocardial injury was limited to the subgroup of patients with ≥ 2 tests performed within 12 hours of presentation. Cardiac troponin was measured with a single high-sensitivity cardiac troponin I assay, and we recognize that the performance of rule-in thresholds for myocardial infarction is likely to differ for other assays. Last, the approach to patient selection for cardiac troponin testing will vary across health care systems, and we recommend some caution in extrapolating the performance of rule-in thresholds to sites where testing is performed more widely.

CONCLUSIONS

Although we observed important differences in the kinetics, cardiac troponin concentrations at presentation are insufficient to distinguish type 1 myocardial infarction from other causes of myocardial injury or infarction in practice. Clinical context may be more helpful than any rule-in threshold for guiding initial triage and management decisions.

ARTICLE INFORMATION

Received April 26, 2021; accepted June 7, 2021.

Affiliations

British Heart Foundation Centre for Cardiovascular Science (R.W., C.T., D.D., K.K.L., M.T.H.L., A.B., T.F., A.A., A.R.C., N.L.M.) and Usher Institute (D.M.K., D.D., N.L.M.), University of Edinburgh, UK. University of Glasgow, School of Medicine, UK (D.J.L.). Depart-

ment of Laboratory Medicine and Pathology, Hennepin Healthcare/Hennepin County Medical Center and University of Minnesota, Minneapolis (F.S.A.). Department of Clinical Blood Sciences and Cardiology, St. George's University of London, UK (P.O.C.).

Acknowledgments

R.W., F.S.A., P.O.C., D.M.K., A.R.C., and N.L.M. conceived the study and its design. R.W., D.M.K., and A.R.C. had access to the data and performed the analysis. R.W., D.M.K., A.R.C., and N.L.M. interpreted the data and drafted the article. All authors revised the article critically for important intellectual content and provided their final approval of the version to be published. All authors are accountable for the work. The authors thank the High-STEACS Investigators for their contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work.

Sources of Funding

The High-STEACS trial was funded by a Special Project Grant from the British Heart Foundation (SP/12/10/29922). Dr Wereski, Dr Bularga, and D. Doudesis are supported by Clinical Research Training Fellowships (MR/V007017/1, MR/V007254/1) and a PhD studentship (MR/N013166/1) from the Medical Research Council. Dr Lee is supported by a Clinical Research Training Fellowship (FS/18/25/33454) from the British Heart Foundation. Dr Kimenai is supported by a grant from Health Data Research UK, which receives its funding from Health Data Research UK Ltd (HDR-5012) funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust. Dr Chapman receives support from a Starter Grant for Clinical Lecturers by the Academy of Medical Sciences (SGL021/1075). Dr Mills is supported by the Butler British Heart Foundation Senior Clinical Research Fellowship (FS/16/14/32023) and a Program Grant (RG/20/10/34966) and Research Excellence Award (RE/18/5/34216) from the British Heart Foundation. Abbott Laboratories provided cardiac troponin assay reagents, calibrators, and controls without charge. The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclosures

Dr Apple reports research grants awarded to the Minneapolis Medical Research Foundation from Abbott Diagnostics, Siemens Diagnostics, Ortho-Clinical Diagnostics, and Beckman Coulter outside the submitted work and personal fees from HyTest Ltd. Dr Mills has received honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and LumiraDx, and the University of Edinburgh has received research grants from Abbott Diagnostics and Siemens Healthineers. The other authors report no conflicts.

Supplemental Materials

Expanded Methods
Supplemental Figures I and II
Supplemental Table I

REFERENCES

1. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction (2018). *Eur Heart J*. 2019;40:237–269. doi: 10.1016/j.jacc.2018.08.1038
2. Chapman AR, Adamson PD, Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Berry C, Findlay I, Cruikshank A, et al; High-STEACS Investigators. High-sensitivity cardiac troponin and the universal definition of myocardial infarction. *Circulation*. 2020;141:161–171. doi: 10.1161/CIRCULATIONAHA.119.042960
3. Shah ASV, Sandoval Y, Noaman A, Sexter A, Vaswani A, Smith SW, Gibbins M, Griffiths M, Chapman AR, Strachan FE, et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. *BMJ*. 2017;359:j4788. doi: 10.1136/bmj.j4788
4. Mills NL, Lee KK, McAllister DA, Churchhouse AM, MacLeod M, Stoddart M, Walker S, Denvir MA, Fox KA, Newby DE. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. *BMJ*. 2012;344:e1533. doi: 10.1136/bmj.e1533
5. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, Anand A, Fersia O, Joshi NV, et al. Sensitive troponin assay and the classification of myocardial infarction. *Am J Med*. 2015;128:493–501. e3. doi: 10.1016/j.amjmed.2014.10.056
6. Sandoval Y, Jaffe AS. Type 2 myocardial infarction: *JACC Review Topic of the Week*. *J Am Coll Cardiol*. 2019;73:1846–1860. doi: 10.1016/j.jacc.2019.02.018
7. McCarthy CP, Vaduganathan M, Januzzi JL Jr. Type 2 myocardial infarction: diagnosis, prognosis, and treatment. *JAMA*. 2018;320:433–434. doi: 10.1001/jama.2018.7125
8. DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DA. Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury. *Circulation*. 2019;140:1661–1678. doi: 10.1161/CIRCULATIONAHA.119.040631
9. Taggart C, Wereski R, Mills NL, Chapman AR. Diagnosis, investigation and management of patients with acute and chronic myocardial injury. *J Clin Med*. 2021;10:2331. doi: 10.3390/jcm10112331
10. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130:2354–2394. doi: 10.1161/CIR.0000000000000133
11. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J*. 2020;1–79. doi: 10.1093/eurheartj/ehaa575
12. Chapman AR, Sandoval Y. Type 2 myocardial infarction: evolving approaches to diagnosis and risk-stratification. *Clin Chem*. 2021;67:61–69. doi: 10.1093/clinchem/hvaa189
13. Boeddinghaus J, Twerenbold R, Nestelberger T, Koechlin L, Wussler D, Meier M, Troester V, Zimmermann T, Badertscher P, Wildi K, et al; APACE Investigators. Clinical use of a new high-sensitivity cardiac troponin I assay in patients with suspected myocardial infarction. *Clin Chem*. 2019;65:1426–1436. doi: 10.1373/clinchem.2019.304725
14. Boeddinghaus J, Nestelberger T, Twerenbold R, Neumann JT, Lindahl B, Giannitsis E, Sörensen NA, Badertscher P, Jann JE, Wussler D, et al; APACE, BACC, and TRAPID-AMI Investigators. Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. *Eur Heart J*. 2018;39:3780–3794. doi: 10.1093/eurheartj/ehy514
15. Boeddinghaus J, Reichlin T, Cullen L, Greenlade JH, Parsonage WA, Hammett C, Pickering JW, Hawkins T, Aldous S, Twerenbold R, et al. Two-hour algorithm for triage toward rule-out and rule-in of acute myocardial infarction by use of high-sensitivity cardiac troponin I. *Clin Chem*. 2016;62:494–504. doi: 10.1373/clinchem.2015.249508
16. Twerenbold R, Neumann JT, Sörensen NA, Ojeda F, Karakas M, Boeddinghaus J, Nestelberger T, Badertscher P, Rubini Giménez M, Puelacher C, et al. Prospective validation of the 0/1-h algorithm for early diagnosis of myocardial infarction. *J Am Coll Cardiol*. 2018;72:620–632. doi: 10.1016/j.jacc.2018.05.040
17. Sandoval Y, Smith SW, Schulz K, Sexter A, Apple FS. Rapid identification of patients at high risk for acute myocardial infarction using a single high-sensitivity cardiac troponin I measurement. *Clin Chem*. 2020;66:620–622. doi: 10.1093/clinchem/hvaa045
18. Cullen LA, Mills NL, Mahler S, Body R. Early rule-out and rule-in strategies for myocardial infarction. *Clin Chem*. 2017;63:129–139. doi: 10.1373/clinchem.2016.254730
19. Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P, Greenberg BH, Filippatos G, Davison BA, Cotter G, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. *Eur J Heart Fail*. 2015;17:1262–1270. doi: 10.1002/ejhf.341
20. Thelin J, Melander O. Dynamic high-sensitivity troponin elevations in atrial fibrillation patients might not be associated with significant coronary artery disease. *BMC Cardiovasc Disord*. 2017;17:169. doi: 10.1186/s12872-017-0601-7
21. Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. *Heart*. 2017;103:10–18. doi: 10.1136/heartjnl-2016-309530
22. Sandoval Y, Smith SW, Schulz K, Murakami MM, Love SA, Nicholson J, Apple FS. Diagnosis of type 1 and type 2 myocardial infarction using a high-sensitivity cardiac troponin I assay with sex-specific 99th percentiles based on the third universal definition of myocardial infarction classification system. *Clin Chem*. 2015;61:657–663. doi: 10.1373/clinchem.2014.236638

23. Sandoval Y, Smith SW, Sexter A, Schulz K, Apple FS. Use of objective evidence of myocardial ischemia to facilitate the diagnostic and prognostic distinction between type 2 myocardial infarction and myocardial injury. *Eur Heart J Acute Cardiovasc Care*. 2020;9:62–69. doi: 10.1177/2048872618787796
24. Wereski R, Chapman AR, Lee KK, Smith SW, Lowe DJ, Gray A, Mills NL. High-sensitivity cardiac troponin concentrations at presentation in patients with ST-segment elevation myocardial infarction. *JAMA Cardiol*. 2020;5:1302–1304. doi: 10.1001/jamacardio.2020.2867
25. Healthcare Improvement Scotland. Scottish Intercollegiate Guidelines Network (SIGN) 93: acute coronary syndrome national clinical guideline: SIGN guidelines. 2013. Accessed July 13, 2021. <https://www.sign.ac.uk/our-guidelines/>
26. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al; ESC Committee for Practice Guidelines. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2011;32:2999–3054. doi: 10.1093/eurheartj/ehr236
27. Bularga A, Lee KK, Stewart S, Ferry AV, Chapman AR, Marshall L, Strachan FE, Cruickshank A, Maguire D, Berry C, et al. High-sensitivity troponin and the application of risk stratification thresholds in patients with suspected acute coronary syndrome. *Circulation*. 2019;140:1557–1568. doi: 10.1161/CIRCULATIONAHA.119.042866
28. Sandoval Y, Smith SW, Shah AS, Anand A, Chapman AR, Love SA, Schulz K, Cao J, Mills NL, Apple FS. Rapid rule-out of acute myocardial injury using a single high-sensitivity cardiac troponin I measurement. *Clin Chem*. 2017;63:369–376. doi: 10.1373/clinchem.2016.264523
29. Chin CW, Shah AS, McAllister DA, Joanna Cowell S, Alam S, Langrish JP, Strachan FE, Hunter AL, Maria Choy A, Lang CC, et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. *Eur Heart J*. 2014;35:2312–2321. doi: 10.1093/eurheartj/ehu189
30. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruickshank A, Reid A, Stoddart M, Strachan F, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *BMJ*. 2015;350:g7873. doi: 10.1136/bmj.g7873
31. Than MP, Pickering JW, Sandoval Y, Shah ASV, Tsanas A, Apple FS, Blankenberg S, Cullen L, Mueller C, Neumann JT, et al. Machine learning to predict the likelihood of acute myocardial infarction. *Circulation*. 2019;899–909. doi: 10.1161/CIRCULATIONAHA.119.041980
32. National Institute of Clinical Excellence. Acute coronary syndromes. *NICE Guidelines*. National Institute of Clinical Excellence; 2020: NG185.
33. Apple FS, Collinson PO, Kavsak PA, Body R, Ordóñez-Llanos J, Saenger AK, Omland T, Hammarsten O, Jaffe AS; IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Getting cardiac troponin right: appraisal of the 2020 European Society of Cardiology guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-Segment elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. *Clin Chem*. 2021;67:730–735. doi: 10.1093/clinchem/hvaa337
34. Chapman AR, Anand A, Boeddinghaus J, Ferry AV, Sandeman D, Adamson PD, Andrews J, Tan S, Cheng SF, D'Souza M, et al. Comparison of the efficacy and safety of early rule-out pathways for acute myocardial infarction. *Circulation*. 2017;135:1586–1596. doi: 10.1161/CIRCULATIONAHA.116.025021
35. Haller PM, Boeddinghaus J, Neumann JT, Sørensen NA, Hartikainen TS, Gößling A, Nestelberger T, Twerenbold R, Lehmacher J, Keller T, et al. Performance of the ESC 0/1-h and 0/3-h algorithm for the rapid identification of myocardial infarction without ST-elevation in patients with diabetes. *Diabetes Care*. 2020;43:460–467. doi: 10.2337/dc19-1327
36. Twerenbold R, Badertscher P, Boeddinghaus J, Nestelberger T, Wildi K, Puelacher C, Sabti Z, Rubini Gimenez M, Tschirky S, du Fay de Lavallaz J, et al. 0/1-Hour triage algorithm for myocardial infarction in patients with renal dysfunction. *Circulation*. 2018;137:436–451. doi: 10.1161/CIRCULATIONAHA.117.028901
37. Twerenbold R, Costabel JP, Nestelberger T, Campos R, Wussler D, Arbucci R, Cortes M, Boeddinghaus J, Baumgartner B, Nickel CH, et al. Outcome of applying the ESC 0/1-hour algorithm in patients with suspected myocardial infarction. *J Am Coll Cardiol*. 2019;74:483–494. doi: 10.1016/j.jacc.2019.05.046
38. Pickering JW, Greenslade JH, Cullen L, Flaws D, Parsonage W, Aldous S, George P, Worster A, Kavsak PA, Than MP. Assessment of the European Society of Cardiology 0-hour/1-hour algorithm to rule-out and rule-in acute myocardial infarction. *Circulation*. 2016;134:1532–1541. doi: 10.1161/CIRCULATIONAHA.116.022677
39. Anand A, Lee KK, Chapman AR, Ferry AV, Adamson PD, Strachan FE, Berry C, Findlay I, Cruickshank A, Reid A, et al; HISTORIC Investigators. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a stepped-wedge cluster randomized controlled trial. *Circulation*. 2021;143:2214–2224. doi: 10.1161/CIRCULATIONAHA.120.052380
40. Chew DP, Lambrakis K, Blyth A, Seshadri A, Edmonds MJR, Briffa T, Cullen LA, Quinn S, Karnon J, Chuang A, et al. A randomized trial of a 1-hour troponin t protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible Acute Coronary Syndrome in the Emergency Department With High-Sensitivity Troponin T Study (RAPID-TnT). *Circulation*. 2019;140:1543–1556. doi: 10.1161/CIRCULATIONAHA.119.042891
41. Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, Sandeman D, Stables CL, Adamson PD, Andrews JPM, et al; High-STEACS Investigators. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *Lancet*. 2018;392:919–928. doi: 10.1016/S0140-6736(18)31923-8
42. Jaeger C, Wildi K, Twerenbold R, Reichlin T, Rubini Gimenez M, Neuhaus JD, Grimm K, Boeddinghaus J, Hillinger P, Nestelberger T, et al. One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. *Am Heart J*. 2016;171:92–102.e1. doi: 10.1016/j.ahj.2015.07.022
43. Chiang C-H, Chiang C-H, Gi W-T, Wu Y-K, Huang S-S, Yeo YH, Lee C-C. Safety and efficacy of the European Society of Cardiology 0/1-hour algorithm for diagnosis of myocardial infarction: systematic review and meta-analysis. *Heart*. 2020;106:985–991. doi: 10.1136/heartjnl-2019-316343
44. Hartikainen TS, Sorensen NA, Haller PM, Gößling A, Lehmacher J, Zeller T, Blankenberg S, Westermann D, Neumann JT. Clinical application of the 4th Universal Definition of Myocardial Infarction. *Eur Heart J*. 2020;41:2209–2216. doi: 10.1093/eurheartj/ehaa035
45. Sandoval Y, Thordsen SE, Smith SW, Schulz KM, Murakami MM, Pearce LA, Apple FS. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. *Eur Heart J Acute Cardiovasc Care*. 2014;3:317–325. doi: 10.1177/2048872614538411
46. Neumann JT, Twerenbold R, Ojeda F, Sørensen NA, Chapman AR, Shah ASV, Anand A, Boeddinghaus J, Nestelberger T, Badertscher P, et al. Application of high-sensitivity troponin in suspected myocardial infarction. *N Engl J Med*. 2019;380:2529–2540. doi: 10.1056/NEJMoa1803377
47. Body R, Carlton E, Sperrin M, Lewis PS, Burrows G, Carley S, McDowell G, Buchan I, Greaves K, Mackway-Jones K. Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts. *Emerg Med J*. 2017;34:349–356. doi: 10.1136/emermed-2016-205983